Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Why AI drug discovery has an IP problem and what can be done
Pharma
Why AI drug discovery has an IP problem and what can be done
Can AI tools raise the bar for inventiveness? And when algorithms become as productive as living systems, will they make their own outputs unpatentable? Industry experts unpick AI drug discovery’s biggest issues.   6 October 2025
Simmons & Simmons patent litigator jumps ship
Careers
Simmons & Simmons patent litigator jumps ship
Life sciences specialist boosts its London office with an expert in small molecules, biologics, and gene therapy before UK courts, the UPC, and the EPO.   3 October 2025
IP agencies vital to pharma and biotech grind to a halt
Americas
IP agencies vital to pharma and biotech grind to a halt
From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.   2 October 2025
Careers
Womble Bond Dickinson partners jump to rival firm
Duo have a combined 60 years of experience in patent litigation, prosecution, and patent portfolio management across mechanical, electrical, medical devices, chemical and pharmaceutical tech.   30 September 2025
Europe
EPO ruling clarifies appeal rights, blocking third-party intervention
A landmark decision sees the European Patent Office confirm that once all original appeals are withdrawn, third-party interveners cannot continue proceedings.   30 September 2025
Americas
Biotech sues AstraZeneca and Cellectis over mRNA patents
Complaint alleges the pair used Massachusetts company’s patented mRNA TALEN gene-editing technology without permission in multi-billion-dollar cancer therapy deals.   29 September 2025
Europe
Budgets, CRISPR, and keeping pace with tech: top challenges for Europe’s patent pros
A new survey from LSIPR reveals that European patent practitioners are grappling with client budget constraints and fast-evolving technologies, with most expecting patenting challenges to increase over the next five years.   25 September 2025
Careers
Mewburn expands AI and medtech expertise with London hire
The firm’s Technology & Engineering team will be expanded with an expert in patent drafting, prosecution and opposition/defence work across AI, digital health and medical devices.   25 September 2025
Americas
AbbVie faces secrets lawsuit over $2.1bn Capstan deal
A biotech firm specialising in mRNA therapies alleges AbbVie’s $2.1 billion Capstan purchase was built on stolen lipid nanoparticle trade secrets.   24 September 2025
Americas
MSD scores second win in patent fight over Keytruda
The pharma giant invalidates a university's patent while gaining FDA approval for a new subcutaneous version of Keytruda as it protects its $29.5-billion-a-year cancer drug ahead of a looming patent cliff.   22 September 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.